Botanics: a potential source of new therapies for Alzheimer's disease?

References

• Dastmalchi K, Dorman HJD, Vuorela H, Hiltunen R. Plants as potential sources for drug development against Alzheimer’s disease. Intl J Biomed Pharma Sci. 2007;1(2):83–104.
   Google Scholar
• Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631–639.
   PubMed Web of Science ®Google Scholar
• Yoo KY, Park SY. Terpenoids as potential anti-Alzheimer’s Disease therapeutics. Molecules. 2012;17(3):3524–3538.
   PubMed Web of Science ®Google Scholar
• Estrada LD, Soto C. Disrupting β-Amyloid aggregation for Alzheimer Disease treatment. Curr Top Med Chem. 2007;7(1):115–126.
   PubMed Web of Science ®Google Scholar
• Smith MA, Taneda S, Richey PL, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A. 1994;91(12):5710–5714.
   Web of Science ®Google Scholar
• Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increasedin Alzheimer’s disease. J Neurochem. 1997;68(5):2092–2097.
   Web of Science ®Google Scholar
• Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A. 1991;88(23):10540–10543.
   PubMed Web of Science ®Google Scholar
• Perry G, Cash AD, Smith MA. Alzheimer disease and oxidative stress. J Biomed Biotechnol. 2002;2(3):120–123.
   PubMedGoogle Scholar
• Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–147.
   PubMed Web of Science ®Google Scholar
• Choi BW, Ryu G, Park SH, et al. Anticholinesterase activity of plastoquinones from Sargassum sagamianum: Lead compounds for Alzheimer’s disease therapy. Phytother Res. 2007;21(5):423–426.
   PubMed Web of Science ®Google Scholar
• Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17(2):117–126.
   Web of Science ®Google Scholar
• Lleó A. Current therapeutic options for Alzheimer’s disease. Curr Genomics. 2007;8(8):550–558.
   Web of Science ®Google Scholar
• Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010; 345(1–2):91–104.
   PubMed Web of Science ®Google Scholar
• Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421.
   PubMed Web of Science ®Google Scholar
• Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol. 2005;37(2):289–305.
   PubMed Web of Science ®Google Scholar
• Schott JM, Revesz T. Inflammation in Alzheimer’s disease: insights from immunotherapy. Brain. 2013;136(Pt 9):2654–2656.
   Google Scholar
• Sheng JG, Mrak RE, Griffin WS. Microglial interleukin-1 expression in brain regions in Alzheimer’s disease: correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol. 1995;21(4):290–301.
   Web of Science ®Google Scholar
• Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005;26(3):349–354.
   PubMed Web of Science ®Google Scholar
• Eckert A, Keil U, Marques CA, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer’s disease. Biochem Pharmacol. 2003;66(8):1627–1634.
   PubMed Web of Science ®Google Scholar
• Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A. Amyloid beta peptide of Alzheimer’s disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci. 1996;16(23):7533–7539.
   PubMed Web of Science ®Google Scholar
• Dean E. Apoptosis in neurodegeneration: Programmed cell death and its role in Alzheimer’s and Huntington’s Diseases. Eukaryon. 2008;4:42–47.
   Google Scholar
• Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28(4):202–208.
   PubMed Web of Science ®Google Scholar
• de la Torre JC. Alzheimer’s disease is a vasocognopathy: a new term to describe its nature. Neurol Res. 2004;26(5):517–524.
   PubMed Web of Science ®Google Scholar
• Gorelick PB. Risk factors for vascular dementia and Alzheimer’s disease. Stroke. 2004;35(11 Suppl 1):2620–2622.
   Web of Science ®Google Scholar
• Zlokovic BV. Clearing amyloid through the blood–brain barrier. J Neurochem. 2004;89(4):807–811.
   PubMed Web of Science ®Google Scholar
• Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid b protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci. 2001;21(2):372–381.
   PubMed Web of Science ®Google Scholar
• Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3(89):89ra57.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, De Strooper B. Alzheimer’s disease: A breach in the blood-brain barrier. Nature. 2012;485(7399):451–452.
   Web of Science ®Google Scholar
• Singh AK, Gupta A, Mishra AK, Gupta V, Bansal P, Kumar S. Medicinal plant for curing Alzheimer’s Disease. Intl J of Pharm Biol Arch. 2010;1(2):108–114.
   Google Scholar
• Perry EK, Pickering AT, Wang WW, Houghton P, Perry NS. Medicinal plants and Alzheimer’s disease: Integrating ethnobotanical and contemporary scientific evidence. J Altern Complement Med. 1998;4(4):419–428.
   PubMed Web of Science ®Google Scholar
• Houghton PJ. The role of plants in traditional medicine and current therapy. J Altern Complement Med. 1995;1(2):131–143.
   PubMedGoogle Scholar
• Zhao Q, Brett M, Osselaer VN, et al. Galantamine Pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J Clin Pharmacol. 2002;42(9):1002–1010.
   PubMed Web of Science ®Google Scholar
• Atamna H, Frey WH. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease. Mitochondrion. 2007;7(5):297–310.
   Web of Science ®Google Scholar
• Mancuso C, Scapagnini G, Currò D, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci. 2007;12:1107–1123.
   PubMed Web of Science ®Google Scholar
• Bhullar KS, Rupasinghe HPV. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev. 2013; 2013:1–18.
   Web of Science ®Google Scholar
• Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J Nutr Biochem. 2004;15(9):506–516.
   PubMed Web of Science ®Google Scholar
• Albarracin SL, Stab B, Casas Z, et al. Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci. 2012;15(1):1–9.
   PubMed Web of Science ®Google Scholar
• Orhan I, Aslan M. Appraisal of scopolamine-induced antiamnesic effect in mice and in vitro antiacetylcholinesterase and antioxidant activities of some traditionally used Lamiaceae plants. J Ethnopharmacol. 2009; 122(2):327–332.
   PubMed Web of Science ®Google Scholar
• Patel VR, Patel PR, Kajal SS. Antioxidant activity of some selected medicinal plants in western region of India. Adv Biol Res (Rennes). 2010;4(1):23–26.
   Google Scholar
• Sultana B, Anwar F, Przybylski R. Antioxidant activity of phenolic components present in barks of Azadirachta indica, Terminalia arjuna, Acacia nilotica, and Eugenia jambolana Lam. trees. Food Chem. 2007;104(3):1106–1114.
   Web of Science ®Google Scholar
• Souza JNS, Silva EM, Loir A, Rees JF, Rogez H, Larondelle Y. Antioxidant capacity of four polyphenol-rich Amazonian plant extracts: A correlation study using chemical and biological in vitro assays. Food Chem. 2008;106(1):331–339.
   Web of Science ®Google Scholar
• Amoo SO, Aremu AO, Moyo M, Staden JV. Antioxidant and acetylcholinesterase-inhibitory properties of long-term stored medicinal plants. BMC Complement Altern Med. 2012;12:87.
   PubMed Web of Science ®Google Scholar
• Mokbel MS, Hashinaga F. Evaluation of the antioxidant activity of extracts from buntan (Citrus grandis Osbeck) fruit tissues. Food Chem. 2006;94(4):529–534.
   Web of Science ®Google Scholar
• Arruda M, Viana H, Rainha N, et al. Anti-acetylcholinesterase and antioxidant activity of essential oils from Hedychium gardnerianum Sheppard ex Ker-Gawl. Molecules. 2012;17(3):3082–3092.
   Web of Science ®Google Scholar
• Ved HS, Best JM, Dave JR, Doctor BP. Comparative inhibition of acetylcholinesterase by Tacrine, Physostigmine and Huperzine in the adult rat brain, In. Quinn DM, Balasubramanian AS, Doctor BP, Taylor P, editors. Enzymes of the Cholinesterase Family, Part VII. Philadelphia, PA, USA; Springer US. 1995;477–478.
   Google Scholar
• Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses and activities relevant to the management of Alzheimer’s disease and other cognitive disorders. Phytother Res. 2003;17(1):1–18.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine. 2007;14(4):289–300.
   PubMed Web of Science ®Google Scholar
• Coulibaly AY, Sombie PAED, Tibiri A, Kiendrebeogo M, Compaore MMY, Nacoulma OG. Protective effect of Scoparia dulcis on brain and erythrocytes. Curr Res J Biol Sci. 2011;3(3):254–261.
   Google Scholar
• Miyazawa M, Watanabe H, Kameoka H. Inhibition of acetylcholinesterase activity by monoterpenoids with a p-menthane skeleton. J Agric Food Chem. 1997;45(3):677–679.
   Web of Science ®Google Scholar
• Ahirwar S, Tembhre M, Gour S, Namdeo A. Anticholinesterase Efficacy of Bacopa monnieri against the Brain Regions of Rat – A novel approach to therapy for Alzheimer’s disease. Asian J Exp Sci. 2012;26(1):65–70.
   Google Scholar
• Grundy DL, Still CC. Inhibition of acetylcholinesterases by pulegone-1, 2-epoxide. Pestic Biochem Physiol. 1985;23(3):383–388.
   Web of Science ®Google Scholar
• Hou YC, Chao PD, Chen SY. Honokiol and manolol increased hippocampal acetylcholine release in freely moving rats. Am J Chin Med. 2000;28(3–4):379–384.
   Web of Science ®Google Scholar
• Ferreira A, Proença C, Serralheiro ML, Araújo ME. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. J Ethnopharmacol. 2006;108(1):31–37.
   PubMed Web of Science ®Google Scholar
• Wang YE, Yue DX, Tang XC. [Anti-cholinesterase activity of huperzine A]. Zhongguo Yao Li Xue Bao. 1986;7(2):110–113. Chinese.
   Web of Science ®Google Scholar
• Ren Y, Houghton P, Hider RC, Howes MJ. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorrhiza. Planta Med. 2004;70(3):201–204.
   PubMed Web of Science ®Google Scholar
• Ghosal S, Bhattacharya SK, Mehta R. Naturally occurring and synthetic β-Carbolines as cholinesterase inhibitors. J Pharm Sci. 1972;61(5):808–810.
   Web of Science ®Google Scholar
• Choudhary MI, Nawaz SA, Zaheer-ul-Haq, et al. Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer’s disease therapy. Biochem Biophys Res Commun. 2005;332(4):1171–1177.
   Web of Science ®Google Scholar
• Khalid A, Zaheer-ul-Haq, Anjum S, Khan MR, Atta-ur-Rahman, Choudhary MI. Kinetics and structure–activity relationship studies on pregnane-type steroidal alkaloids that inhibit cholinesterases. Bioorg Med Chem. 2004;12(9):1995–2003.
   Web of Science ®Google Scholar
• Dall’Acqua S. Plant-derived acetylcholinesterase inhibitory alkaloids for the treatment of Alzheimer’s disease. Botanics: Targets and Therapy. 2013;3:19–28.
   Google Scholar
• Attar-ur-Rahman, Atia-Tul-Wahab, Nawaz SA, Choudhary MI. New cholinesterase inhibiting Bisbenzylisoquinoline alkaloids from Cocculus pendulus. Chem Pharm Bull (Tokyo). 2004;52(7):802–806.
   Web of Science ®Google Scholar
• Ahmad VU, Khan A, Farooq U, et al. Three new cholinesterase-inhibiting cis-clerodane diterpenoids from Otostegia limbata. Chem Pharm Bull (Tokyo). 2005;53(4):378–381.
   Web of Science ®Google Scholar
• Lee KY, Yoon JS, Kim ES, Kang SY, Kim YC. Anti-acetylcholinesterase and anti-amnesic activities of a pregnane glycoside, Cynatroside B, from Cynanchum atratum. Planta Med. 2005;71(1):7–11.
   Web of Science ®Google Scholar
• Khalid A, Azim MK, Parveen S, Atta-ur-Rahman, Choudhary MI. Structural basis of acetylcholinesterase inhibition by triterpenoidal alkaloids. Biochem Biophys Res Commun. 2005;331(4):1528–1532.
   Web of Science ®Google Scholar
• Andrade MT, Lima JA, Pinto AC, Rezende CM, Carvalho MP, Epifanio RA. Indole alkaloids from Tabernaemontana australis (Müell. Arg) Miers that inhibit acetylcholinesterase enzyme. Bioorg Med Chem. 2005;13(12):4092–4095.
   Web of Science ®Google Scholar
• Park CH, Kim SH, Choi W, et al. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Med. 1996;62(5):405–409.
   Web of Science ®Google Scholar
• Chung YK, Heo HJ, Kim EK, et al. Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol Cells. 2001;11(2):137–143.
   PubMed Web of Science ®Google Scholar
• Orhan I, Terzioglu S, Sener B. Alpha-onocerin: an acetylcholinesterase inhibitor from Lycopodium clavatum. Planta Med. 2003;69(3):265–267.
   Web of Science ®Google Scholar
• Heo HJ, Kim MJ, Lee JM, et al. Naringenin from Citrus junos has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia dementia. Dement Geriatr Cogn Disord. 2004;17(3):151–157.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Iwasaki K, Furukawa K, et al. Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer’s beta-amyloid proteins. J Neurosci Res. 2006;84(2):427–433.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Tabuchi M, Yamaguchi T, et al. A traditional medicinal herb Paeonia suffruticosa and its active constituent 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose have potent anti-aggregation effects on Alzheimer’s amyloid beta proteins in vitro and in vivo. J Neurochem. 2009;109(6):1648–1657.
   PubMed Web of Science ®Google Scholar
• Papandreou MA, Kanakis CD, Polissiou MG, et al. Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem. 2006;54(23):8762–8768.
   PubMed Web of Science ®Google Scholar
• Durairajan SS, Yuan Q, Xie L, et al. Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty. Neurochem Int. 2008;52(4–5):741–750.
   Web of Science ®Google Scholar
• Kang IJ, Jeon YE, Yin XF, et al. Butanol extract of Ecklonia cava prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death. Food Chem Toxicol. 2011;49(9):2252–2259.
   Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892–5901.
   PubMed Web of Science ®Google Scholar
• Feng Y, Yang SG, Du XT, et al. Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun. 2009;390(4):1250–1254.
   Web of Science ®Google Scholar
• Gupta VB, Indi SS, Rao KS. Garlic extract exhibits antiamyloidogenic activity on amyloid-β fibrillogenesis: relevance to Alzheimer’s disease. Phytother Res. 2009;23(1):111–115.
   Web of Science ®Google Scholar
• Niidome T, Takahashi K, Goto Y, et al. Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity. Neuroreport. 2007;18(8):813–816.
   Web of Science ®Google Scholar
• Schott JM, Revesz T. Inflammation in Alzheimer’s disease: insights from immunotherapy. Brain. 2013;136(Pt 9):2654–2656.
   Google Scholar
• Parajuli B, Sonobe Y, Horiuchi H, Takeuchi H, Mizuno T, Suzumura A. Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer’s disease. Cell Death Dis. 2013;4(12):e975.
   Google Scholar
• Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer’s disease. Annu Rev Med. 1996;47:401–411.
   PubMed Web of Science ®Google Scholar
• Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer’s disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995;16(4):523–530.
   PubMedGoogle Scholar
• Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer’s type. Br J Rheumatol. 1989;28(1):86–88.
   Google Scholar
• McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335(8696):1037.
   Web of Science ®Google Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–432.
   PubMed Web of Science ®Google Scholar
• Howes MJ, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav. 2003;75(3):513–527.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang LN, Du QM, et al. Akebia Saponin D attenuates amyloid β-induced cognitive deficits and inflammatory response in rats: involvement of Akt/NF-κB pathway. Behav Brain Res. 2012;235(2):200–209.
   PubMed Web of Science ®Google Scholar
• Grzanna R, Phan P, Polotsky A, Lindmark L, Frondoza CG. Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. J Altern Complement Med. 2004;10(6):1009–1013.
   Web of Science ®Google Scholar
• Zhang L, Fiala M, Cashman J, et al. Curcuminoids enhance amyloid-β uptake by macrophages of Alzheimer’s disease patients. J Alzheimers Dis. 2006;10(1):1–7.
   PubMed Web of Science ®Google Scholar
• Giri RK, Rajagopal V, Kalra VK. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem. 2004;91(5):1199–1210.
   PubMed Web of Science ®Google Scholar
• Pendurthi UR, Rao LV. Suppression of transcription factor Egr-1 by curcumin. Thromb Res. 2000;15;97(4):179–189.
   PubMed Web of Science ®Google Scholar
• Matthew S, Jain AK, James M, Matthew C, Bhowmik D. Analgesic and anti-inflammatory activity of Kalanchoe pinnata (Lam.) Pers. J Med Plants Stud. 2013;1(2):24–28.
   Google Scholar
• Kumari STK, Lincy MP, Muthukumarasamy S, Mohan VR. Anti-inflammatory activity of Sarcostemma secamone (l) bennet whole plant against carrageenan induced paw edema. Bioscience Discovery. 2012;3(3):288–291.
   Google Scholar
• Leal LK, Ferreira AA, Bezerra GA, Matos FJ, Viana GS. Antinociceptive, anti-inflammatory and bronchodilator activities of Brazilian medicinal plants containing coumarin: a comparative study. J Ethnopharmacol. 2000;70(2):151–159.
   Web of Science ®Google Scholar
• Zhang L, Ravipati AS, Koyyalamudi SR, et al. Antioxidant and anti-inflammatory activities of selected medicinal plants containing phenolic and flavonoid compounds. J Agric Food Chem. 2011;59(23):12361–12367.
   PubMed Web of Science ®Google Scholar
• Sharififar F, Khazaeli P, Alli N, Talebian N, Zarehshahi R, Amiri S. Study of antinociceptive and anti-inflammatory activities of certain Iranian medicinal plants. J Intercult Ethnopharmacol. 2012;1(1):19–24.
   Google Scholar
• Kwak HM, Jeon SY, Sohng BH, et al. beta-Secretase (BACE1) inhibitors from pomegranate (Punica granatum) husk. Arch Pharm Res. 2005;28(12):1328–1332.
   Web of Science ®Google Scholar
• Descamps O, Spilman P, Zhang Q, et al. AβPP-selective BACE inhibitors (ASBI):novel class of therapeutic agents for Alzheimer’s Disease. J Alzheimers Dis. 2013;37(2):343–355.
   Web of Science ®Google Scholar
• Ożarowski M, Mikołajczak PL, Bogacz A, Kujawski R, Mrozikiewicz PM. Plants and their chemical compounds affecting β-amyloid and secretase activity as potential sources of neuroprotective herbal medicinal products. Part 1. Herba Polonica. 2010;56(4):91–107.
   Google Scholar
• Hwang EM, Ryu YB, Kim HY, et al. BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008;16(14):6669–6674.
   Web of Science ®Google Scholar
• Jeon SY, Kwon SH, Seong YH, et al. β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine. 2007;14(6):403–408.
   Web of Science ®Google Scholar
• Mandel S, Reznichenko L, Amit T, Youdim MB. Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotox Res. 2003;5(6):419–424.
   PubMed Web of Science ®Google Scholar
• Okello EJ, Savelev SY, Perry EK. In vitro anti-β-secretase and dual anticholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. Phytother Res. 2004;18(8):624–627.
   PubMed Web of Science ®Google Scholar
• Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci. 1999;893:113–125.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang W, Sun YJ, Hu M, Li F, Zhu DY. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood–brain barrier damage. Eur J Pharmacol. 2007;561(1–3):54–62.
   PubMed Web of Science ®Google Scholar
• Virgili F, Kim D, Packer L. Procyanidins extracted from pine bark protects alpha-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett. 1998;431(3):315–318.
   PubMed Web of Science ®Google Scholar
• Zeng LH, Wu J, Fung B, Tong JH, Mickle D, Wu TW. Comparative protection against oxyradicals by three flavonoids on cultured endothelial cells. Biochem Cell Biol. 1997;75(6):717–720.
   Web of Science ®Google Scholar
• Gerritsen ME, Carley WW, Ranges GE, et al. Flavonoids inhibit cytokine induced endothelial cell adhesion protein gene expression. Am J Pathol. 1995;147(2):278–292.
   PubMed Web of Science ®Google Scholar
• Youdim KA, McDonald J, Kalt W, Joseph JA. Potential role of dietary flavonoids in reducing microvascular endothelium vulnerability to oxidative and inflammatory insults (small star, filled). J Nutr Biochem. 2002;13(5):282–288.
   PubMed Web of Science ®Google Scholar
• Bonoiu A, Mahajan SD, Ye L, et al. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009;1282:142–155.
   PubMed Web of Science ®Google Scholar
• Tahanian E, Sanchez LA, Shiao TC, Roy R, Annabi B. Flavonoids targeting of IκB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells. Drug Des Devel Ther. 2011;5:299–309.
   Web of Science ®Google Scholar
• Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci. 1997;20(4):154–159.
   PubMed Web of Science ®Google Scholar
• Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR. Alzheimer’s disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord. 2005;4(4):383–403.
   PubMedGoogle Scholar
• Lee YK, Yuk DY, Lee JW, et al. (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res. 2009;1250:164–174.
   PubMed Web of Science ®Google Scholar
• Findeis MA, Schroeder F, McKee TD, et al. Discovery of a novel pharmacological and structural class of γ-Secretase modulators derived from the extract of Actaea racemosa. ACS Chem Neurosci. 2012;3(11):941–951.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Cavalli A, Valgimigli L, et al. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease. J Med Chem. 2007;50(26):6446–6449.
   PubMed Web of Science ®Google Scholar
• Janle EM, Lila MN, Grannan M, et al. Pharmacokinetics and tissue distribution of 14C-labeled grape polyphenols in the periphery and the central nervous system following oral administration. J Med Food. 2010;13(4):926–933.
   PubMed Web of Science ®Google Scholar
• Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl). 1998;138(3–4):217–230.
   Web of Science ®Google Scholar
• Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl. 2000;176:68–73.
   PubMedGoogle Scholar
• Ye JC, Zeng S, Zheng GL, Chen GS. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm. 2008;356(1–2):187–192.
   PubMed Web of Science ®Google Scholar
• Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Rev. 1998;4(2):87–136.
   Google Scholar
• Ntie-Kang F, Mbah JA, Lifongo LL, et al. Assessing the pharmacokinetic profile of the CamMedNP natural products database: an in silico approach. Org Med Chem Lett. 2013;3(1):10.
   PubMedGoogle Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998;20(4):634–647.
   PubMed Web of Science ®Google Scholar
• Razay G, Wilcock GK. Galantamine in Alzheimer’s disease. Expert Rev Neurother. 2008;8(1):9–17.
   PubMedGoogle Scholar
• Maelicke A, Hoeffle-Maas A, Ludwig J, et al. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci. 2010;40(1–2):135–137.
   PubMed Web of Science ®Google Scholar
• Ha GT, Wong RK, Zhang Y. Huperzine a as potential treatment of Alzheimer’s disease: an assessment on chemistry, pharmacology, and clinical studies. Chem Biodivers. 2011;8(7):1189–1204.
   PubMed Web of Science ®Google Scholar
• Rajakrishnan V, Viswanathan P, Rajasekharan KN, Menon VP. Neuroprotective role of curcumin from curcuma longa on ethanol-induced brain damage. Phytother Res. 1999;13(7):571–574.
   PubMed Web of Science ®Google Scholar
• Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int. 2009;54(2):111–118.
   PubMed Web of Science ®Google Scholar
• Williams P, Sorribasa A, Howes MJ. Natural products as a source of Alzheimer’s drug leads. Nat Prod Rep. 2011;28(1):48–77.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and other Dementias. London: European Medicines Agency; 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003562.pdf. Accessed October 12, 2013.
   Google Scholar
• Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy. 2000;20(1):1–12.
   PubMed Web of Science ®Google Scholar
• Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318(7184):633–638.
   PubMed Web of Science ®Google Scholar
• Yang G, Wang Y, Tian J, Liu JP. Huperzine a for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(9):e74916.
   PubMed Web of Science ®Google Scholar
• Wang H, Tang XC. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Acta Pharmacologica Sinica. 1998;19(1):27–30.
   Web of Science ®Google Scholar
• Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a Clinical practice guideline. Ann. Intern. Med. 2008;148(5):379–397.
   PubMed Web of Science ®Google Scholar
• Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer’s disease. Psychopharmacol Bull. 1992;28(1):61–66.
   Google Scholar
• Zanotti A, Valzelli L, Toffano G. Chronic phosphatidylserine treatment improves spatial memory and passive avoidance in aged rats. Psychopharmacology (Berl). 1989;99(3):316–321.
   Web of Science ®Google Scholar
• Kudolo GB, Dorsey S, Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb Res. 2002;108(2–3):151–160.
   Web of Science ®Google Scholar
• Valikovics A, Csányi A, Németh L. Study of the effects of vinpocetin on cognitive functions. Ideggyogy Sz. 2012;65(3–4):115–120.
   Google Scholar
• Park SY. Potential therapeutic agents against Alzheimer’s disease from natural sources. Arch Pharm Res. 2010;33(10):1589–1609.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Mills T, Carr D, et al. Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenet Genomics. 2007;17(12):1091–1100.
   PubMed Web of Science ®Google Scholar
• Tsuno N. Donepezil in the treatment of patients with Alzheimer’s disease. Expert Rev Neurother. 2009;9(5):591–598.
   PubMed Web of Science ®Google Scholar
• Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders – memantine, a new hope. Pharmacol Res. 2005;51(1):1–17.
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer’s Disease. N Engl J Med. 2003;348:1333–1341.
   PubMed Web of Science ®Google Scholar
• Mei Z, Zhang F, Tao L, et al. Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett. 2009;452(2):90–95.
   Web of Science ®Google Scholar
• Peng Y, Sun J, Hon S, et al. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer’s disease. J Neurosci. 2010;30(24):8180–8189.
   PubMed Web of Science ®Google Scholar
• Marumoto S, Miyazawa M. Beta-secretase inhibitory effects of furanocoumarins from the root of Angelica dahurica. Phytother Res. 2010;24(4):510–513.
   Web of Science ®Google Scholar
• Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JS. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol Pharm Bull. 2009;32(8):1433–1438.
   PubMed Web of Science ®Google Scholar
• Rates SM. Plants as source of drugs. Toxicon. 2001;39(5):603–613.
   PubMed Web of Science ®Google Scholar
• Donnelly AC. Marine Natural Products as Anticancer Agents: Therapeutic Treasures from the Deep. American Chemical Society Division of Organic Chemistry; 2010. Available from: http://www.organicdivision.org/ama/orig/Fellowship/2009_2010_Awardees/Essays/Donnelly.pdf. Accessed January 6, 2014.
   Google Scholar
• Rein MJ, Renouf M, Cruz-Hernandez C, Actis-Goretta L, Thakkar SK, da Silva Pinto M. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. Br J Clin Pharmacol. 2012;75(3):588–602.
   Web of Science ®Google Scholar